Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
BOSTON, Sept. 05, 2017 -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Paresh Soni, MD, PhD, Chief Medical Officer, is scheduled to present at the 19th Annual Rodman & Renshaw Global Investment Conference at the Lotte New York Palace in New York City on Monday, September 11, 2017, at 9:10 a.m. EDT.
A live audio webcast of the presentation will be accessible from the Investors page of Albireo’s website, http://ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo’s website for at least two weeks following the event.
For more information about the conference, visit: www.rodmanevents.com.
About Albireo
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes a Phase 3 product candidate, a Phase 2 product candidate and a product candidate for which an application for regulatory approval has been submitted in Japan. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Source: Albireo Pharma, Inc.
Investor Contact: Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568 Media Contact: Heather Anderson 6 Degrees 980-938-0260 [email protected]
